Veerhealth Care Secures ₹3.6 Crore Skincare Manufacturing Order

MUMBAI — Mumbai-headquartered pharmaceutical and consumer wellness manufacturer Veerhealth Care Limited has secured a significant domestic institutional supply contract valued at ₹360 Lakhs (₹3.6 Crores) to manufacture specialized face care formulations.

The corporate announcement, finalized on June 9, 2026, marks an important milestone for the enterprise as it expands its footprint within India's highly competitive Fast-Moving Consumer Goods (FMCG) manufacturing ecosystem. Moving forward under a tight, contractually mandated execution timeline, the manufacturer will utilize its dedicated industrial production plants to fulfill the volume requirements within the ongoing fiscal quarter.

Technical Specifications and Execution Parameters of the Contract

According to formal compliance filings submitted to the Bombay Stock Exchange, the complete value of the commercial order stands at ₹360 Lakhs, calculated strictly exclusive of statutory Goods and Services Tax (GST) allocations. The contract falls entirely under domestic jurisdiction, highlighting robust institutional procurement demand within India's internal personal care and consumer products market.

Operationally, the contract requires rapid manufacturing and delivery deployment. The core terms mandate that Veerhealth Care must completely execute the product formulation, packaging, and structural logistics distribution framework within a strict 45-day window from the date of final order formalization.

The production run will focus specifically on specialized face care products. To maintain corporate commercial confidentiality between the transacting parties, the specific identity of the major Indian FMCG conglomerate presenting the commercial mandate has been withheld by the company under non-disclosure terms.

Regulatory Compliance and Governance Verifications

The regulatory notification was filed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs material corporate announcements.

The filing cleared several important regulatory checks regarding corporate governance:

Manufacturing Base and Capacity Utilization Context

To meet the high-volume requirements of this institutional FMCG order, Veerhealth Care will deploy its primary manufacturing infrastructure located at Plot No. 224, Vibrant Business Park, in Vapi, Gujarat. This industrial facility specializes in compounding, processing, and packaging personal care products, cosmetics, and traditional healthcare formulas under strict quality standards.

The transaction shows that major national consumer brands are increasingly outsourcing production to specialized third-party manufacturers that have established operations in regulatory-compliant manufacturing zones like southern Gujarat. This arrangement allows large FMCG corporations to lower their capital expenditures while leveraging local manufacturing agility to scale up cosmetic lines quickly.

Official Sources Section

The financial parameters, commercial timelines, and corporate compliance metrics detailed in this report are sourced from official institutional records:

• The transaction details follow the formal corporate announcement signed by Bhavin S. Shah, Managing Director of Veerhealth Care Limited.

• Public market reporting was completed through the disclosure system ofBSE Limitedunder corporate Scrip Code: 511523.

• Regulatory tracking metrics match the requirements set by theSecurities and Exchange Board of India (SEBI)Master Circular on listing obligations.

Executive Commentary on Financial Outlook

Company leadership indicated that securing this contract will improve short-term capacity utilization and positively impact the company's full-year financial performance.

"This new order represents a significant opportunity for the Company and we anticipate additional growth in turnover," stated Bhavin S. Shah, Managing Director of Veerhealth Care Limited, in the official corporate disclosure.

Why It Matters to Investors and Markets

For small-cap equity investors, this contract provides clear near-term revenue visibility, as the ₹3.6 crore order will convert into cash flow within the mandatory 45-day cycle. The transaction also proves that Veerhealth Care's manufacturing facilities are capable of meeting the stringent quality and volume demands of top-tier FMCG brands, which could open doors to more lucrative, multi-year supply partnerships.

Key Facts at a Glance

• Total Order Value: Valued at ₹360 Lakhs (₹3.6 Crores), excluding applicable national GST calculations.

• Execution Timeline: The contract requires the company to manufacture and supply the items within a 45-day period.

• Target Category: The manufacturing run focuses exclusively on consumer face care products.

• Production Location: Manufacturing will take place at the company's specialized consumer healthcare facility in Vapi, Gujarat.

FAQ Section

Who awarded the ₹3.6 crore skincare manufacturing contract to Veerhealth Care?

The contract was awarded by a prominent domestic Indian Fast-Moving Consumer Goods (FMCG) company. However, the specific identity remains undisclosed due to confidentiality clauses in the agreement.

What is the exact timeline for completing this product order?

Veerhealth Care is contractually required to manufacture, process, and completely supply the face care product line within 45 days from the formal signing of the order.

Does this transaction involve related party interests?

No. The company has explicitly confirmed to the stock exchange that no promoters, promoter groups, or related sister companies hold any interest in the entity that awarded this contract.

Source: Veerhealth Care Limited Investor Relations Compliance File, BSE Limited Corporate Announcement Repository, Securities and Exchange Board of India Public Portal